ALFA Finder| Management target | Revenue 100.0% FY27 |
|---|
| Revenue growth | 22% YoY; 28% QoQ. |
|---|---|
| Margins | EBITDA margin improved to 14.6% from 14.1% YoY. |
| Order book | Annual cost-plus contracts; ₹90-100 Cr service revenue visibility. |
| Demand visibility | Strong; shifting revenue mix towards higher-margin services (40% vs 30% YoY). |
| Management confidence | High; bullish on healthcare industry and integrated PSP-camps model. |
Growth
Consolidated revenue grew 22% YoY to ₹56.9 Cr; PAT rose 25% YoY to ₹4 Cr; EBITDA grew 27% to ₹8.3 Cr.
Outlook
Maintains FY27 revenue guidance of ₹220 Cr; targets 18% EBITDA margin. PSP revenue visibility at ₹90-100 Cr for FY27.
Risks
Higher employee costs due to upfront hiring for new PSP contracts; reliance on pharmaceutical company marketing budgets.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue ~INR173 Cr → delivered INR172.9 Cr (= BEAT)
- Guided 15% EBITDA margin for FY26 → delivered 15% (= BEAT)
- Guided doubling service revenue → delivered 31% mix (INR50+ Cr) (= BEAT)
Partly delivered
- Guided INR13-16 Cr camp revenue → delivered INR13 Cr (= PARTIAL)
Missed
- Guided 17% EBITDA margin earlier in FY26 → delivered 15% (= MISS)
Earnings Call Transcript filed with NSE, NSE: QMSMEDI. Summary written with AI assistance from the document.
QMS Medical Allied Services Ltd: key numbers
- Share price
- ₹170.59
- Market cap
- ₹329.9 Cr
- Revenue (annual)
- ₹172.9 Cr
- Net profit (annual)
- ₹11.92 Cr
- P/E (TTM)
- 27.7×Sector 54.5×
- Promoter holding
- 68.11%+0.00% QoQ
- FII holding
- 0.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from QMS Medical Allied Services Ltd
All →QMS Medical Allied Services Annual General Meeting
QMS Medical Allied Services Limited held its 9th Annual General Meeting on September 30, 2026. Shareholders approved a 5% final dividend and adoption of financial results.
QMS Medical Allied Services Acquisition
QMS Medical Allied Services Limited is acquiring BeamOptics Scientific Private Limited. The strategic acquisition aims to expand the company's addressable market in healthcare business.
- Execution
- on or before 30th November, 2027
QMS Medical Allied Services Business Update
QMS Medical Allied Services executed a shareholders' agreement with investors and its subsidiary, Saarathi Healthcare, defining governance rights, veto powers, and share transfer restrictions.
QMS Medical Allied Services Merger & Restructuring
QMS Medical Allied Services Limited approved a composite demerger scheme for its healthcare business and the acquisition of a 100% stake in BeamOptics Scientific Private Limited.
QMS Medical Allied Services Acquisition Worth ₹14.22 Cr
QMS Medical Allied Services Ltd acquired the remaining 24% stake in Saarathi Healthcare Private Limited for Rs. 14.23 Crore, making it a wholly-owned subsidiary.
- Value
- ₹14.22 Cr
QMS Medical Allied Services Other Announcement
QMS Medical Allied Services Limited informed the exchange regarding the dispatch of annual report links to shareholders who haven't registered their email addresses.